Primary signet ring cell carcinoma of the appendix: A rare case report and our 18-year experience

World Journal of Gastroenterology

Volumn 14, Issue 37, 2008, Pages 5763-5768

  Ko, Yoon Ho ^a   Jung, Chan Kwon ^b   Oh, Soon Nam ^b   Kim, Tae Hee ^a   Won, Hye Sung ^a   Kang, Jin Hyoung ^a   Kim, Hyung Jin ^b   Kang, Won Kyung ^b   Oh, Seong Taek ^b   Hong, Young Seon ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Appendiceal neoplasms; Carcinoma; Chemotheraphy; Signet' ring cell

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT;

AGED; APPENDECTOMY; APPENDIX CARCINOMA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CASE REPORT; FEMALE; HUMAN; INOPERABLE CANCER; LAPAROSCOPIC SURGERY; MULTIPLE CYCLE TREATMENT; OVARY METASTASIS; PERITONEUM METASTASIS; SALPINGOOOPHORECTOMY; SIGNET RING CARCINOMA; ADJUVANT CHEMOTHERAPY; ADULT; APPENDIX TUMOR; COMPUTER ASSISTED TOMOGRAPHY; MALE; METASTASIS; MIDDLE AGED; OVARIECTOMY; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APPENDECTOMY; APPENDICEAL NEOPLASMS; CARCINOMA, SIGNET RING CELL; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; PERITONEAL NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 63449118190     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.5763     Document Type: Article

References (28)

1. McCusker ME, Cote TR, Clegg LX, Sobin LH. Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973-1998. Cancer 2002; 94: 3307-3312
2. McGory ML, Maggard MA, Kang H, O'Connell JB, Ko CY. Malignancies of the appendix: beyond case series reports. Dis Colon Rectum 2005; 48: 2264-2271
3. Connor SJ, Hanna GB, Frizelle FA. Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies. Dis Colon Rectum 1998; 41: 75-80
4. O'Donnell ME, Badger SA, Beattie GC, Carson J, Garstin WI. Malignant neoplasms of the appendix. Int J Colorectal Dis 2007; 22: 1239-1248
5. Glehen O, Mohamed F, Sugarbaker PH. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg 2004; 240: 278-285
6. Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol 2008; 34: 196-201
7. Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei". Am J Surg Pathol 1995; 19: 1390-1408
8. Misdraji J, Young RH. Primary epithelial neoplasms and other epithelial lesions of the appendix (excluding carcinoid tumors). Semin Diagn Pathol 2004; 21: 120-133
9. Percy C, Van Holten V, Muir C, editors. International Classification of Diseases for Oncology (ICD-O). 2nd edition. Geneva: World Health Organization, 1990. Available from: URL: http://www.who.int/ classifications/icd/en/
10. Higa E, Rosai J, Pizzimbono CA, Wise L. Mucosal hyperplasia, mucinous cystadenoma, and mucinous cystadenocarcinoma of the appendix. A re-evaluation of appendiceal "mucocele". Cancer 1973; 32: 1525-1541
11. Djuranovic SP, Spuran MM, Kovacevic NV, Ugljesic MB, Kecmanovic DM, Micev MT. Mucinous cystadenoma of the appendix associated with adenocarcinoma of the sigmoid colon and hepatocellular carcinoma of the liver: report of a case. World J Gastroenterol 2006; 12: 1975-1977
12. Nonaka D, Kusamura S, Baratti D, Casali P, Younan R, Deraco M. CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases. Histopathology 2006; 49: 381-387
13. Park IJ, Yu CS, Kim HC, Kim JC. [Clinical features and prognostic factors in primary adenocarcinoma of the appendix] Korean J Gastroenterol 2004; 43: 29-34
14. Ronnett BM, Yan H, Kurman RJ, Shmookler BM, Wu L, Sugarbaker PH. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 2001; 92: 85-91
15. Nitecki SS, Wolff BG, Schlinkert R, Sarr MG. The natural history of surgically treated primary adenocarcinoma of the appendix. Ann Surg 1994; 219: 51-57
16. Murphy EM, Farquharson SM, Moran BJ. Management of an unexpected appendiceal neoplasm. Br J Surg 2006; 93: 783-792
17. Cortina R, McCormick J, Kolm P, Perry RR. Management and prognosis of adenocarcinoma of the appendix. Dis Colon Rectum 1995; 38: 848-852
18. Sugarbaker PH. Cytoreductive surgery and intraperitoneal chemotherapy with peritoneal spread of cystadenocarcinoma. Eur J Surg Suppl 1991; 75-82
19. Sugarbaker PH. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 2001; 27: 239-243
20. Yan TD, Bijelic L, Sugarbaker PH. Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms. Ann Surg Oncol 2007; 14: 2289-2299
21. Gonzalez-Moreno S, Sugarbaker PH. Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. Br J Surg 2004; 91: 304-311
22. Ishibashi K, Sobajima J, Okada N, Ishizuka N, Yokoyama M, Mitsuhashi T, Miyazaki T, Nakada H, Gonda T, Ishida H. [A case of pseudomyxoma peritonei successfully treated with multidisciplinary treatment including modified FOLFOX6 regimen] Gan To Kagaku Ryoho 2007; 34: 2047-2049
23. James P. Phase III randomized study of operative debulking and systemic chemotherapy with or without intra- and peri-operative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from low-grade gastrointestinal adenocarcinoma. Available from: URL: http://www.cancer.gov/clinicaltrials/NCI-03-C-0085
24. Rosen LS. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist 2005; 10: 382-391
25. O'Connell JT, Tomlinson JS, Roberts AA, McGonigle KF, Barsky SH. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells. Am J Pathol 2002; 161: 551-564
26. Perrais M, Pigny P, Copin MC, Aubert JP, Van Seuningen I. Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor/Ras/Raf/extracellular signal-regulated kinase cascade and Sp1. J Biol Chem 2002; 277: 32258-32267
27. Andreopoulou E, Muggia F, Safa M, Escalon J, Downey A, Newman E, Hochster H, Wojtaszek C, Mauro D, Lowy A. Phase II study of cetuximab in mucinous peritoneal carcinomatosis. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 14020. org/cgi/content/abstract/24/18≻ppl/14020
28. Logan-Collins JM, Lowy AM, Robinson-Smith TM, Kumar S, Sussman JJ, James LE, Ahmad SA. VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon. Ann Surg Oncol 2008; 15: 738-744